

CombiGene featured in an article in Nature, one of the world's leading scientific journals

The latest number of Nature (Vol. 564, Issue 7735, 13 December 2018) features CombiGene's operations, and the possibilities of using gene therapy to treat epilepsy. Both CombiGene's scientific founder, Professor Merab Kokaia, and CEO Jan Nilsson, are quoted.

"CombiGene being featured in Nature like this makes me incredibly happy and proud. It is a clear sign that our research and development is beginning to attract international attention. With this fantastic end of 2018, we will start 2019 stronger and even more inspired," says CombiGene CEO Jan Nilsson.



Merab Kokaia, Scientific founder



Jan Nilsson, CEO

Read the entire article here:

<https://www.nature.com/magazine-assets/d41586-018-07644-y/d41586-018-07644-y.pdf>

About CombiGene AB

CombiGene's business concept is to develop effective gene therapies for treatment of difficult-to-treat diseases for which adequate treatment methods are currently lacking. The company intends to take its candidate drugs through the phases of preclinical development and initial clinical studies under its own management, and subsequently continue development and commercialization in collaboration with other partners. Founded on the basis of scientific discoveries made at Lund University and the University of Copenhagen, CombiGene has offices at Medicon Village in Lund, Sweden. The company is public and listed on the Swedish marketplace Spotlight. www.combigene.com

For further information:

CombiGene AB (publ)
Jan Nilsson, CEO
Phone: +46 (0)704 66 31 63
Email: jan.nilsson@combigene.com

MORE FROM THE COMPANY is a newsletter from CombiGene which contains general news and information that is judged not to have a significant effect on the share price. Other issues of MORE FROM THE COMPANY and PRESS RELEASES are available at www.combigene.com